Amylyx Pharmaceuticals Inc (AMLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has a cash flow conversion efficiency ratio of -0.135x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.88 Million) by net assets ($273.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AMLX equity to assets ratio to measure how much of total assets are equity-financed.
Amylyx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Amylyx Pharmaceuticals Inc (AMLX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Amylyx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Global Partners LP
NYSE:GLP
|
-0.114x |
|
Jiangsu Zhangjiagang Rural Commercial Bank Co Ltd
SHE:002839
|
0.253x |
|
Elvalhalcor Hellenic Copper and Aluminium Industry S.A
AT:ELHA
|
0.104x |
|
IMAX Corporation
F:IMA
|
0.009x |
|
Gujarat State Petronet Limited
NSE:GSPL
|
0.104x |
|
Hyosung Corp
KO:004800
|
0.117x |
|
Merchants Bancorp
NASDAQ:MBIN
|
0.013x |
|
Guangdong Orient Zirconic Ind Sci & Tech Co Ltd
SHE:002167
|
0.092x |
Annual Cash Flow Conversion Efficiency for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see AMLX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.26 Million | $-123.34 Million | -0.404x | +60.29% |
| 2024-12-31 | $164.76 Million | $-167.65 Million | -1.017x | -3800.09% |
| 2023-12-31 | $433.43 Million | $11.92 Million | 0.027x | +105.21% |
| 2022-12-31 | $340.61 Million | $-179.87 Million | -0.528x | -206.73% |
| 2021-12-31 | $-151.17 Million | $-74.80 Million | 0.495x | -10.03% |
| 2020-12-31 | $-66.72 Million | $-36.70 Million | 0.550x | +30.49% |
| 2019-12-31 | $-25.36 Million | $-10.69 Million | 0.421x | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more